Pr A. Eggermont

Pr of Oncology

MD, PhD

Head of Clinical & Translational Immunotherapies. UMC (University MC), Utrecht (NL); Chief Scientific Officier. Pediatric oncology center Princessa Maxima, Utrecht. (NL)

Past President of EORTC, ECCO, of the European Academy of Cancer Sciences.

Past CEO Gustave Roussy. Eur J Cancer Editor in Chief

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens